Results 21 to 30 of about 15,116 (246)

Antinociceptive effects of carbidopa levodopa on normal rats and Parkinson’s disease mice

Pakistan Journal of Pharmaceutical Sciences, 2023
Carbidopa levodopa is widely used to ameliorate motor symptoms of Parkinson's disease (PD) patients. Pain is one of common symptoms of PD. The aim of this experiment is to study antinociceptive effects of carbidopa levodopa on normal rats and PD mice ...
Zhang Wenbo, Ma Zhigang, Zhang Jiren, Zhang Ce, Li Ting, Zhang Pinyuan, Wang Tian   +6 more
doaj   +1 more source

Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.

PLoS ONE, 2020
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication.
Jin Yong Hong, Mun Kyung Sunwoo, Jung Han Yoon, Suk Yun Kang, Young H Sohn, Phil Hyu Lee, Seo Hyun Kim   +6 more
doaj   +1 more source

Rapid Electrochemical Detection of Levodopa using Polyaniline-Modified Screen-Printed Electrodes for the Improved Management of Parkinson\u27s Disease [PDF]

, 2022
A portable test to rapidly determine levels of levodopa, the drug used to treat Parkinson’s disease, can improve clinical management of the disease. In this study, screen-printed electrodes were modified with polymers to facilitate the electrochemical ...
Craig, Banks, Jake, McClements, Henrique, Noguchi, Jonas, Gruber, James, Dawson, Sarbjeet, Kaur, Pankaj, Singla, Helena, Snyder, Katarina, Novakovic, Luiza, Krettli, Marloes, Peeters, Inderpreet, Kaur, Robert, Crapnell   +12 more
core   +1 more source

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis

Journal of Parkinson’s Disease, 2021
Background: The widely divergent responsiveness of Parkinson’s disease (PD) patients to levodopa is an important clinical issue because of its relationship with quality of life and disease prognosis.
Cheng Zhou, Tao Guo, JingJing Wu, Linbo Wang, Xueqin Bai, Ting Gao, Xiaojun Guan, Luyan Gu, Peiyu Huang, Min Xuan, Quanquan Gu, Xiaojun Xu, Baorong Zhang, Wei Cheng, Jianfeng Feng, Minming Zhang   +15 more
doaj   +1 more source

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics

Current Therapeutic Research, 2020
: Background: Parkinson's disease is a neurodegenerative disorder, and a major cause of disability. Levodopa, a prodrug of dopamine, remains the gold standard in the pharmacological management of Parkinson's disease.
Benedicta Obenewaa Dankyi, MPhil, Seth Kwabena Amponsah, PhD, Grace Lovia Allotey-Babington, PhD, Ismaila Adams, BPharm, Nana Aboadwe Goode, BPharm, Henry Nettey, PharmD/PhD   +5 more
doaj   +1 more source

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

npj Parkinson's Disease, 2021
Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund, Lukas Pavelka, Rianne A. J. Esselink, Ben P. M. Geurtz, Ron A. Wevers, Brit Mollenhauer, Rejko Krüger, Bastiaan R. Bloem, Marcel M. Verbeek   +8 more
doaj   +1 more source

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes

Cells, 2021
Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli, Abel Fothi, Ester Nespoli, Istvan Liko, Borbala Veto, Piroska Devay, Flora Szeri, Bastian Hengerer, Csaba Barta, Tamas Aranyi   +9 more
doaj   +1 more source

Levodopa-responsive chorea: A review

Annals of Indian Academy of Neurology, 2020
Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj   +1 more source

Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations

npj Parkinson's Disease, 2023
The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes   +6 more
doaj   +1 more source

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Cells, 2022
The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede   +3 more
doaj   +1 more source